(Q43109275)

14 November 2017

Cognitive enhancement therapy for a model of Down syndrome (English)

1 reference

14 November 2017

Frances K Wiseman

1

1 reference

PubMed ID

20368181

14 November 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

Science Translational Medicine

14 November 2017

1 reference

14 November 2017

1

1 reference

14 November 2017

7

1 reference

14 November 2017

7ps9

1 reference

Down syndrome--recent progress and future prospects

14 November 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Restoration of norepinephrine-modulated contextual memory in a mouse model of Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

The proteins of human chromosome 21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

A mouse model for Down syndrome exhibits learning and behaviour deficits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Some morphometric observations on the brains of patients with Down's syndrome: their relationship to age and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

The locus coeruleus and noradrenergic modulation of cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Meta-analysis of suicide-related behavior events in patients treated with atomoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Prevalence of dementia and impact on intellectual disability services.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Disease-specific patterns of locus coeruleus cell loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Effects of Donepezil on Cognitive Functioning in Down Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Down syndrome and Alzheimer disease: response to donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: a clinical report series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

Education and children with Down syndrome: neuroscience, development, and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3000449

10.1126/SCITRANSLMED.3000449

21 January 2018

Identifiers

DOI

1 reference

14 November 2017

1 reference

PubMed ID

20368181